CELL INTELLIGENCE · 肿瘤细胞治疗研究

对关于“持续性细胞因子释放综合征与复发/难治性淋巴瘤成人患者接受 CD19 靶向 CAR-T 细胞治疗后低纤维蛋白原血症相关”一文的来信的回复

Response to the Letter regarding "Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in

更正：抗 CD19 CAR-T 细胞治疗日本高级别 B 细胞淋巴瘤的有效性：单中心分析

Correction: Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

R-GDP 方案作为复发/难治性弥漫大 B 细胞淋巴瘤挽救化疗的疗效

Efficacy of R-GDP therapy as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.

弥漫大 B 细胞淋巴瘤 axicabtagene ciloleucel 治疗后持续性帕金森综合征伴多巴胺能去神经支配：一例病例报告

Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report.

迟发性人类疱疹病毒 6 型脑炎伴继发性噬血细胞性淋巴组织细胞增生症发生于 CAR-T 细胞治疗后

Late-onset Human Herpesvirus 6 Encephalitis with Secondary Hemophagocytic Lymphohistiocytosis after CAR T-cell Therapy.

抗 CD19 CAR-T 细胞治疗日本高级别 B 细胞淋巴瘤的疗效：单中心分析

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

CAR-T 细胞疗法在 R/R HGBCL 患者中的疗效仍不理想。高级别形态学可能有助于识别 CAR-T 细胞治疗后预后特别差的高风险患者。

体重指数与 CD19CAR-T 细胞治疗复发/难治性 B 细胞淋巴瘤后结局：一项全国性注册研究

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

CAR-T 细胞治疗后类似眼眶淋巴瘤复发的假性进展

Pseudoprogression after CAR T-cell therapy mimicking orbital lymphoma relapse.

异基因造血干细胞移植在化疗、CAR-T 治疗和 PD-1 阻断失败后的难治性原发性纵隔大 B 细胞淋巴瘤中实现完全缓解

Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failur